SCHEMBL409685

SCHEMBL409685

CNc1c(NC)c(=O)c1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15700688 0.84 — —
SCHEMBL26059323 0.84 — —
SCHEMBL463072 0.84 — —
SCHEMBL12569505 0.84 — —
SCHEMBL12784271 0.80 CXCR2 (0.35) —
SCHEMBL16683780 0.80 CXCR2 (0.36) —
SCHEMBL12801445 0.80 GRIN2D (0.32) —
SCHEMBL791197 0.77 — —
SCHEMBL2874352 0.77 — —
SCHEMBL2874349 0.77 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024073106-A1 COMPOUNDS AND COMPOSITIONS USEFUL AS INHIBITORS OF TAPS TRACT PHARMACEUTICALS, INC. (US) 2024-04-04 — — WO disclosed
US-20240016953-A1 TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS SEAGEN INC (US) 2024-01-18 — — US disclosed
US-20240016953-A1 TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS SEAGEN INC (US) 2024-01-18 — — US disclosed
US-20230357133-A1 NANOMATERIALS COMPRISING CARBONATES BEAM THERAPEUTICS INC. 2023-11-09 — — US disclosed
US-20230357133-A1 NANOMATERIALS COMPRISING CARBONATES BEAM THERAPEUTICS INC. 2023-11-09 — — US disclosed
US-20230346951-A1 MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS YALE UNIVERSITY 2023-11-02 — — US disclosed
US-20230348362-A1 LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS Suzhou Abogen Biosciences Co., Ltd. (CN) 2023-11-02 — — US disclosed
US-11773061-B2 Cyclic lipids and methods of use thereof RENAGADE THERAPEUTICS MANAGEMENT INC. (US) 2023-10-03 — — US disclosed
WO-2023183616-A1 NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME SENDA BIOSCIENCES, INC. (US) 2023-09-28 — — WO disclosed
WO-2023133645-A1 RADIOLABELED COMPOUNDS FOR IMAGING OF FIBROBLAST ACTIVATION PROTEIN (FAP) AND TREATMENT OF FAP-RELATED DISORDERS PROVINCIAL HEALTH SERVICES AUTHORITY (CA) 2023-07-20 — — WO disclosed
US-7780953-B2 Compositions magnetic particles covered with gem-bisphosphonate derivatives GUERBET (FR) 2010-08-24 — — US disclosed
US-7780953-B2 Compositions magnetic particles covered with gem-bisphosphonate derivatives GUERBET (FR) 2010-08-24 — — US disclosed
WO-2010092114-A1 USE OF BUFFERS FOR RADIONUCLIDE COMPLEXATION GUERBET (FR) 2010-08-19 — — WO disclosed
US-20100143250-A1 COMPOUNDS FOR THE DIAGNOSIS OF APOPTOSIS GUERBET (FR) 2010-06-10 — — US disclosed
WO-2009053597-A2 NOVEL METHOD FOR PREPARING NANOPARTICLES COVERED WITH AN ORGANIC STABILISING LAYER COUPLED TO TARGETING LIGANDS GUERBET (FR) 2009-04-30 — — WO disclosed
WO-2009053596-A2 NOVEL METHOD FOR PREPARING NANOPARTICLES COVERED WITH A GEM-BISPHOSPHONATE STABILISING LAYER COUPLED TO HYDROPHILIC BIODISTRIBUTION LIGANDS GUERBET (FR) 2009-04-30 — — WO disclosed
EP-1572246-B1 NOVEL COMPOSITIONS OF MAGNETIC PARTICLES COVERED WITH GEM-BISPHOSPHONATE DERIVATIVES GUERBET SA (FR) 2009-02-25 — — EP disclosed
WO-2008125464-A1 COMPOUNDS FOR THE DIAGNOSIS OF DISEASES ASSOCIATED WITH VCAM EXPRESSION GUERBET (FR) 2008-10-23 — — WO disclosed
WO-2008125420-A2 COMPOUNDS FOR DIAGNOSING APOPTOSIS GUERBET (FR) 2008-10-23 — — WO disclosed
US-20080015192-A1 INHIBITORS OF POLO-LIKE KINASES ABBVIE INC. 2008-01-17 — — US disclosed
Send feedback